Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

Zimmer Biomet (ZBH) has a Zacks Rank of #3 (Hold), a B Value Style Score and a B VGM Score, with a forward P/E of 11.29. For fiscal 2026, one analyst raised estimates in the past 60 days, while the consensus estimate was unchanged at $8.54 per share; the company’s average earnings surprise is +4.5%. The article presents ZBH as a value-stock candidate, but reports no material consensus estimate increase or share-price reaction.

Analysis

The actionable signal is weak: a valuation screen and a promotional rating are not evidence that Zimmer Biomet’s earnings trajectory is improving. The more relevant detail is that the cited fiscal-2026 consensus was unchanged despite one upward analyst revision; that is not broad estimate momentum. A low forward multiple may reflect market skepticism about durable procedure growth, product-cycle execution, pricing, or share retention—not simply mispricing. Verify current estimates, organic sales by product category, and guidance before treating the valuation as a catalyst.

Over the next days, this article itself is unlikely to support a durable re-rating. Over 1–3 months, earnings revisions, procedure volumes, and management commentary on product launches and market share matter more than the Zacks style label. Over 6–18 months, execution against larger orthopedic competitors such as Stryker and Johnson & Johnson, and the ability to defend pricing while refreshing its portfolio, will determine whether the discount closes. Competitor gains could pressure ZBH even if overall procedure demand remains healthy.

Contrarian read: the value case may be underappreciated if steady procedure demand and improving execution stabilize earnings, but the article offers no evidence that this inflection is underway. Treat ZBH as a watchlist value candidate, not a fresh catalyst trade. The thesis weakens if estimates are cut, organic growth or guidance disappoints, or evidence points to continued share loss; it strengthens with repeated upward revisions and improving operating results.

Key Decisions for Investors

• No immediate trade based on this article; its valuation and ranking claims are not a substitute for a forward earnings catalyst.
• Monitor the next earnings release for organic sales and procedure growth, product-category performance, guidance, and management commentary on share trends versus Stryker and Johnson & Johnson.
• Revisit a long ZBH only if estimate revisions broaden beyond isolated upward changes and reported execution supports the value thesis; use renewed estimate cuts or weaker guidance as thesis-failure alerts.
• Before sizing any position, verify the current valuation against peers and the company’s recent organic growth and cash-flow trend; these data are missing from the article.